cltlc
![]()
Posts:1
For baseline T790M mutation, is there data regarding efficacy of Tagrisso (AZD9291)? If not, is it expected that baseline T790M would respond like acquired T790M? Is there data regarding combining Tagrisso with chemo for baseline or acquired T790M? Thank you.
Forums
Reply # - January 11, 2016, 05:52 AM
As Dr. West has said:
As Dr. West has said:
“Only a very small proportion of patients with lung cancer have a “de novo” T790M mutation at the time of diagnosis, pre-EGFR inhibitor therapy. These patients tend to not do well with Tarceva (gefitinib) or Iressa (gefitinib), though they should have a much better chance of doing well with AZD9291 or rociletinib.” – http://cancergrace.org/topic/navelbine-hard-to-tolerate#post-1267953
JimC
Forum moderator